Registration is Open | Join us in Houston, TX for AMCP's 2025 Annual Meeting Register Now! Close

Legislation & Regulation

Resource February 28, 2018

AMCP Submits Letter to West Virginia Speaker of Delegates on House Bill 4524 and Establishing Guidelines for the Substitution of Certain Biologic Pharmaceuticals by Pharmacists

AMCP comment letter on state legislation on pharmacist substitution of biologics.

Biosimilars, Formulary Management, Legislation & Regulation, Managed Care Practice Issues

Resource February 28, 2018

AMCP submits letter to Connecticut Senate General Law Committee on Senate Bill 197 regarding Interchangeable Biologic Products

AMCP comment letter on state legislation on interchangeable biologic products.

Biosimilars, Formulary Management, Legislation & Regulation, Managed Care Practice Issues

Resource February 27, 2018

AMCP Submits Letter to Alaska House Finance Committee Regarding Senate Bill 32 and the Regulation of Biologic Product Substitutions

AMCP comments on state legislation on substitution of biologics.

Biosimilars, Formulary Management, Legislation & Regulation, Managed Care Practice Issues

Resource February 27, 2018

AMCP submits letter to Wyoming Joint Labor, Health and Social Services Committee on Senate File 75 and Authorizing Pharmacists to Dispense Interchangeable Biologic Products

AMCP comments on state legislation on interchangeable biologics.

Biosimilars, Formulary Management, Legislation & Regulation, Managed Care Practice Issues

Resource February 12, 2018

AMCP Submits Letter to Speaker of Wisconsin Assembly regarding Assembly Bill 679 and the Regulations on Pharmacists Substituting Biological Products

AMCP comment letter on state legislation on interchangeable biologic products.

Formulary Management, Legislation & Regulation, Managed Care Practice Issues, Biosimilars

Resource January 7, 2018

AMCP sends letter to Michigan House Health Policy Committee citing concerns with HB 4472 and regulations on pharmacists substituting interchangeable biological products

AMCP comments on state legislation on substitution of interchangeable biologics.

Formulary Management, Legislation & Regulation, Managed Care Practice Issues, Biosimilars, Legislation & Regulation